Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 2.6 -1.52% -0.04
APTO closed down 1.52 percent on Friday, September 13, 2019, on 33 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical APTO trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
BB Squeeze Ended Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Support Bullish -1.52%
Bollinger Band Squeeze Range Contraction -1.52%
BB Squeeze + Upper Band Touch Range Contraction -1.52%
Above Upper BB Strength -1.52%
Overbought Stochastic Strength -1.52%
Upper Bollinger Band Touch Strength -1.52%
MACD Bullish Centerline Cross Bullish 0.39%

Older signals for APTO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Medicine Biopharmaceutical Cancer Clinical Medicine Drugs Oncology Solid Tumors Immunotherapy Acute Myeloid Leukemia Pancreatic Cancer Targeted Therapy Bemcentinib Treatment Of Acute Myeloid Leukemia Phosphoinositide 3 Kinase Inhibitor Preclinical Stage Products Pancreatic Cancers Small Molecule Therapies Treatment Of Pancreatic Cancer
Is APTO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.13
52 Week Low 1.57
Average Volume 330,022
200-Day Moving Average 2.1814
50-Day Moving Average 2.5619
20-Day Moving Average 2.4178
10-Day Moving Average 2.475
Average True Range 0.1599
ADX 16.08
+DI 23.4006
-DI 13.7018
Chandelier Exit (Long, 3 ATRs ) 2.2903
Chandelier Exit (Short, 3 ATRs ) 2.6897
Upper Bollinger Band 2.6456
Lower Bollinger Band 2.19
Percent B (%b) 0.9
BandWidth 18.843577
MACD Line 0.0281
MACD Signal Line -0.0088
MACD Histogram 0.0369
Fundamentals Value
Market Cap 62.48 Million
Num Shares 24 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -3.33
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.84
Resistance 3 (R3) 2.84 2.76 2.80
Resistance 2 (R2) 2.76 2.70 2.76 2.79
Resistance 1 (R1) 2.68 2.66 2.64 2.68 2.77
Pivot Point 2.60 2.60 2.58 2.60 2.60
Support 1 (S1) 2.52 2.54 2.48 2.52 2.43
Support 2 (S2) 2.44 2.50 2.44 2.41
Support 3 (S3) 2.36 2.44 2.40
Support 4 (S4) 2.36